ACTR-29. A PHASE 2 STUDY OF TTFIELDS AND PULSED BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA

Despite aggressive treatment comprising surgery, radiation therapy and chemotherapy, the median overall survival (OS) for patients with recurrent GBM averages 25 weeks. Our prior experience in 8 bevacizumab-refractory GBM patients initially treated with TTFields monotherapy and re-challenged with be...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neuro Oncol
Main Authors: Tran, David, Ghiaseddin, Ashley, Campian, Jian, Staal, Stephen, Andrews, Sarah, Warren, Sonisha, Ansstas, George
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2017
Fag:
Abstracts
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692742/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.024
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker